reason report
littl headach robust aimovig trend
point blockbust class
bottom line today publish updat migrain
prevent market model analysi launch trend
amgen aimovig sever call medacorp headach
specialist recent week feedback suggest aimovig
launch strongli although major patient current take
drug remain free-product trial period offer earli
launch trend bode well follow-on entrant space teva
fremanezumab lilli galcanezumab alder eptinezumab
product captur signific share shape
blockbust biopharmaceut categori base kol feedback
initi prescript data aimovig revis cgrp migrain
prevent model forecast global market inject cgrp
medicin reach amgen
aimovig retain greatest share market long term
continu believ four antibodi similar
differ feedback kol suggest aimovig
galcanezumab eptinezumab well-posit commerci
success teva fremanezumab may challeng differenti
self-administ less conveni use physician-
administ somewhat less efficaci set reason
peak market share aimovig lilli galcanezumab
remain higher fremanezumab despit medicin
dose subcutan continu believ alder intraven
antibodi eptinezumab prefer signific subset patient
conserv model peak market share epti low
end rang medacorp kol suggest
drug profil medacorp feedback suggest emerg
data oral cgrp directli threaten inject
instead offer prospect potenti earlier treatment post-acut
stabil event rather true prevent sever
base revis revenu forecast aimovig
fremanezumab eptinezumab updat compani
model mp teva alder op full detail
regard model chang compani describ within
price target unchang teva
unchang alder previous
compani inform leerink partner llc research
pleas refer page import disclosur price chart analyst certif
complet august edt distribut august edt rx trend deriv im
use im prescript data gather initi insight uptak growth trajectori
aimovig sinc launch last week may recent im trend indic demand
aimovig robust earli valu volum aimovig limit high
proport use consist free good initi nbrx new start
volum aimovig impress week launch patient
per week start aimovig week patient
start medicin exhibit full month approv total number
prescript aimovig juli number like doubl
base recent four week nbrx data report im
estim individu activ take aimovig new start
within past month initi week im data appear trend ahead
launch first-in-class self-inject specialti medicin dupix nucala
still earli reliabl estim im captur rate aimovig continu double-digit
growth new-to-brand prescript even enter month market suggest
still bolu phase launch pent demand among known sever
migraneur flow specialti headach center suggest steady-
state new start may reach within next month two demand among
current backlog patient seek treatment met earli trend suggest steady-
state could higher later investor expect
exhibit aimovig prescript data eleven week launch
spoke sever specialist high volum commun academ headach center
around countri get feedback initi uptak patient satisfact aimovig
research suggest demand aimovig consist im rx trend
distinctli advantag competitor first market
opportun lock larg number sever patient
headach specialist spoke came larg neurolog practic alreadi
prescrib aimovig patient receiv consist feedback high
volum physician may written prescript mani sever migrain patient
less prescript fill due week backlog patient
process treatment hub ad vast major
patient tri aimovig date free drug program
program initi offer everi patient two month free drug acknowledg
extend access potenti month depend time approv
reimburs patient insur reason seem like actual revenu
modest next quarter two despit robust uptak market
accord one medacorp kol hire increas hub process
capac allevi initi bottleneck seem peak around mid-juli
kol state patient origin abl start treatment within week
prescrib lag time extend week mani practic
initi use chronic episod botox nave experienc patient
physician feedback suggest initi use aimovig popul
much align fda label concern use inject
anti-cgrp medicin limit chronic migrain patient fail
botox alreadi wherea aimovig label much broader prevent treatment
migrain adult although major initi use free drug seem
physician prescrib aimovig migrain suffer sub-optim control
prevent therapi regardless specif number headach day per month
episod vs chronic prior prevent treatment find treat popul
includ botox experienc botox nave patient inde physician
ad aimovig patient still manag botox residu headach
remain seen whether type patient approv continu treatment
payer told academ headach center proport
migrain patient provid believ elig aimovig high one
interest phenomenon sinc botox approv prevent chronic migrain
popul physician may prefer tri botox initi chronic patient sinc aimovig
alway ad later revers occur start aimovig result
reduct less headach day per month botox approv prevent
medacorp kol indic initi post-approv clinic experi aimovig
posit similar respons describ clinic trial kol
suggest mani patient prefer first inject offic self-
inject subsequ monthli dose small number patient return clinic
start aimovig given typic monthli less frequent visit schedul howev
headach specialist alreadi seen dramat respons heard mani
complaint inject site discomfort treatment failur first dose drug
posit formulari access exploit first mover advantag
migrain panel therapeut day earli juli note specialist
suggest earli stage negoti payer secur formulari
access aimovig aimovig sinc includ nation formulari list express
script anecdot inform larg plan inde
reimburs aimovig provid patient fail least one prevent therapi alreadi
given sizeabl pool patient tri medicin migrain prevent
dearth new altern past coupl year nearli individu
consid aimovig immedi meet modest prior author criteria
howev payer seem inclin contract ahead two
competitor deliv best possibl price migrain beneficiari appear
gambl patient start aimovig via free good program continu
aimovig rather switch anoth anti-cgrp addit drug approv
feedback physician payer suggest mani health plan may includ
inject cgrp medicin formulari formulari ultim evolv
toward includ one three subcutan anti-cgrp plu alder intraven
antibodi eptinezumab secur coverag major payer soon possibl
could give advantag face new entrant worst case patient start
free aimovig provid power advocaci voic reimburs
competit posit highlight previous believ alder may start trial
trial patient continu headach sc anti-cgrp trial
assum signific respons treat switcher patient could give alder rel strong
posit formulari physician treatment hierarchi
physician feedback suggest econom limit impact cgrp prescrib
one often debat topic anti-cgrp class physician choic drug dose
may affect practic patient econom physician administ inject
drug clinic typic retain small signific product mark-up margin well
paid administr fee associ in-offic procedur administr
botox inject migrain kol suggest associ mark-up could
per inject associ fee could also anoth practic
substanti variabl around number major case drug administ
offic favor econom practic compar self-inject medicin
product suppli patient administ patient independ
offic staff bill feedback headach specialist adopt alder
eptinezumab intraven drug class could posit affect
rel econom advantag offic administr specialist consult
launch aimovig provid feedback specialist therapeut day
event juli suggest eptinezumab iv administr could captur share
cgrp market within sever year expect launch base primarili
expect product clinic advantag speed onset depth effect rather
mode administr practic econom
teva lack autoinjector launch hinder uptak
multipl kol spoke suggest inject cgrp market share
among four antibodi soon-to-b approv galcanezumab fremanezumab
teva take share away aimovig kol view aimovig
galcanezumab meaning differ highlight small
signific time-to-market advantag aimovig like factor protect market
share also cgrp receptor antibodi wherea galcanezumab
fremanezumab target receptor ligand thu make teva lilli product
interchang product class
kol spoke skeptic long term prospect teva fremanezumab
cite lack auto-injector present launch major limit factor launch
fact multipl inject requir order achiev monthli dose could
includ label well monthli put teva disadvantag lilli
despit medicin requir monthli administr kol spoke
suggest patient may feel comfort self-administ fremanezumab home
would subcutan option sinc syring
autoinjector present addit less frequent quarterli administr physician
offic may enough increment conveni choos fremanezumab
monthli auto-injector physician also suggest alder product
becom avail may prefer use teva patient look quarterli dose
particularli given eptinezumab slightli faster onset action better efficaci
updat leerink forecast incorpor medacorp feedback im rx data
revis launch long-term forecast anti-cgrp class migrain prevent base
feedback medacorp kol current im prescript data aimovig
convers headach specialist strengthen confid outlook
aimovig size overal inject cgrp class longer term howev report
revenu next year undermin signific discount lilli
teva tri grab initi start long term patient share
believ rate patient start cgrp per week forecast
monthli nbrx growth may continu double-digit percentag rate least anoth
month updat launch trajectori estim individu start aimovig
august number reach per month end year
expect monthli persist stabil around earli mean retent
prior month nbrx dupix nucala result nearli patient take aimovig
end expect modest adopt two inject fourth
quarter year well revis forecast new start growth line launch
trajectori dupix nucala exhibit revis persist estim also
consist two rel recent launch exhibit
exhibit new start proport total prescript time
exhibit monthli persist forecast line subq antibodi
estim proport fill prescript free good current
expect declin end view like modest
proport prescript continu free good even beyond initi
month launch
forecast nearli million individu cgrp antibodi aimovig retain
largest market share longer term market model includ long-term market share
galcanezumab fremanezumab eptinezumab base assumpt
fremanezumab becom second anti-cgrp medicin market
septemb pdufa data market monthli quarterli inject
pre-filled syring teva approv materi delay compani unabl develop
introduc auto-injector within month believ compani outlook
would significantli lower share current forecast would like result
significantli lower share teva competitor
model estim popul chronic migrain patient activ care
million us elig portion moderate-sever episod migrain patient
nearli million anticip initi use inject anti-cgrp medicin skew
toward sever chronic subgroup forecast penetr popul
end compar penetr milder subpopul longer term
believ much chronic migrain patient elig episod migrain
patient receiv inject anti-cgrp medicin prevent result million
individu treat class medicin
revis market model estim global market inject cgrp class
reach forecast aimovig retain largest share
use inject cgrp market longer term follow lilli galcanezumab
teva fremanezumab alder eptinezumab share estim support
extens feedback medacorp specialist review clinic trial data
fda label mention product
leerink revenu forecast teva alder adjust revis penetr net
price share assumpt
revis aimovig forecast lower due lower net price
assumpt modestli increas longer term due greater size cgrp market
forecast global aimovig sale record revenu
novarti balanc aimovig repres total revenu estim
updat revenu forecast remain slightli consensu futur year
without adjust compani model price target amgen
remain maintain market perform rate stock
alder eptinezumab sale minim chang earli year modestli decreas
outer year due slightli share subcutan antibodi slightli lower net price
continu believ epti well posit captur substanti share
inject cgrp market migrain prevent forecast risk-adjust revenu
alder continu assum earli launch risk-adjust
probabl approv assum ex-u approv eptinezumab wont occur
least includ royalti ex-u sale eptinezumab reach
per year includ subcutan formul eptinezumab model
time also updat alder compani model recent quarter result
made minim chang expens forecast futur year revis price target
alder previous maintain outperform rate alder
teva revis forecast fremanezumab slightli lower assum
like need offer slightli higher rebat competit drive market share like
administ physician offic partial off-set slightli higher outlook
overal cgrp class overal estim risk-adjust po sale
total teva sale grow risk-adjust
sale ahead septemb pdufa carri risk time approv
teva api manufactur manufactur issu outstand warn letter
fda updat forecast teva remain slightli consensu sale ep
ep consensu expect rate pt
exhibit profil inject cgrp medicin
developeramgnllyteva ivfrequencymonthlymonthlymonthli quarterlyquarterlypric per ml- healthcar
exhibit revis lp market model cgrp medicin migrain prevent
exhibit quarterli launch forecast cgrp medicin
exhibit long term forecast cgrp medicin class
rate aldr share outperform alder biopharmaceut late stage biotechnolog
compani guid develop lead product eptinezumab monoclon antibodi
seek prophylax migrain eptinezumab member larg emerg class
anti-cgrp anti-calcitonin gene relat peptid cgrp area heavi competit
mp partner nv teva aldr announc posit data
two pivot studi migrain prophylaxi across anti-cgrp
group aldr compani develop iv though expect patient prefer
at-hom administr believ defined/differenti market exist durabl in-offic
infus physician make money beyond iv formul eptinezumab
aldr develop subcutan formul test monthli quarterli dose
estim price target aldr month use dcf analysi dcf
valuat employ discount rate termin growth rate believ
discount rate reason consid clinic stage compani dcf valuat
includ net cash dilut secur addit forecast cash flow believ
eptinezumab grow time achiev global risk-adjust sale
includ royalti outsid us includ probability-of-success iv
peak market share anti-cgrp market
risk valuat includ fda/ema approv risk eptinezumab risk
clinic program delay competit risk given presenc multipl anti-cgrp
antibodi manufactur risk risk disappoint clinic data risk dilut
price target inc stock rate market
perform one first gener pioneer biopharmaceut industri
succeed basi build three massiv revenu pillar legaci product
enbrel face array brand gener competitor mean
associ revenu total like steadili declin offset outlook
number recent develop acquir product growth
profit potenti view unlik match legaci brand least mani year
manag respond challeng restructur compani
expens base initi dividend lever compani balanc sheet cash trap
off-shore gener make legaci product compar peer regard
defens stock also one lack explos upsid potenti typic
associ breakthrough rapidli grow biotherapeut stock
price target inc base averag three approach
believ reason basi valu stock today approach simpl price
earn multipl larg cap us eu larg cap biopharma stock sni
rhhbi gsk nv price sale multipl larg cap biotechnolog pharma
compani novo discount cash flow dcf use rel multipl
larg cap biopharma compani ep appli ep
estim give one year futur valu use establish larg cap
futur revenu multipl sale appli revenu forecast amgen
give futur valu final dcf valuat base current
outlook compani exist product probability-weight revenu contribut
late stage pipelin program discount compani wacc give
fair valu today averag three approach give price target
risk view outlook valuat includ major chang label
price reimburs coverag compani legaci product failur
compani growth portfolio achiev futur sale forecast risk includ develop
delay disappoint earlier stage pipelin asset earlier signific eros
compani legaci product biosimilar innov competit shortfal
compani effort improv oper margin would also materi affect outlook
valuat would larg dilut acquisit therapeut area platform
believ teva remain pressur due overhang long approv
fremanezumab delay continu headwind copaxon sandoz
nv gener potenti other sale declin us
gener outer year believ consensu underestim rate teva
under-perform price target
ebitda ev/ebitda multipl drive teva lower view
higher-than-expect number new gx launch lower-than-expect number competitor
copaxon key brand product austedo fremanezumab perform expect
leerink partner research compani file zack factset consensu
leerink partner research compani file zack factset consensu
leerink partner research compani file zack factset consensu
leerink partner research compani file zack factset consensu
rate aldr share outperform alder biopharmaceut late stage biotechnolog
compani guid develop lead product eptinezumab monoclon antibodi
seek prophylax migrain eptinezumab member larg emerg class
anti-cgrp anti-calcitonin gene relat peptid cgrp area heavi competit
mp partner nv teva aldr announc posit data
two pivot studi migrain prophylaxi across anti-cgrp
group aldr compani develop iv though expect patient prefer
at-hom administr believ defined/differenti market exist durabl in-offic
infus physician make money beyond iv formul eptinezumab
aldr develop subcutan formul test monthli quarterli dose
estim price target aldr month use dcf analysi dcf
valuat employ discount rate termin growth rate believ
discount rate reason consid clinic stage compani dcf valuat
includ net cash dilut secur addit forecast cash flow believ
eptinezumab grow time achiev global risk-adjust sale
includ royalti outsid us includ probability-of-success iv
peak market share anti-cgrp market
risk valuat includ fda/ema approv risk eptinezumab risk
clinic program delay competit risk given presenc multipl anti-cgrp
antibodi manufactur risk risk disappoint clinic data risk dilut
price target inc stock rate market perform
one first gener pioneer biopharmaceut industri
succeed basi build three massiv revenu pillar legaci product
enbrel face array brand gener competitor mean
associ revenu total like steadili declin offset outlook
number recent develop acquir product growth
profit potenti view unlik match legaci brand least mani
year manag respond challeng restructur compani
expens base initi dividend lever compani balanc sheet cash
trap off-shore gener make legaci product compar peer
regard defens stock also one lack explos upsid potenti
typic associ breakthrough rapidli grow biotherapeut stock
price target inc base averag three approach
believ reason basi valu stock today approach simpl price
earn multipl larg cap us eu larg cap biopharma stock sni
rhhbi gsk nv price sale multipl larg cap biotechnolog pharma
compani novo discount cash flow dcf use rel multipl
larg cap biopharma compani ep appli ep
estim give one year futur valu use establish larg cap
futur revenu multipl sale appli revenu forecast amgen
give futur valu final dcf valuat base current
outlook compani exist product probability-weight revenu contribut
late stage pipelin program discount compani wacc give
fair valu today averag three approach give price target
risk view outlook valuat includ major chang label
price reimburs coverag compani legaci product failur
compani growth portfolio achiev futur sale forecast risk includ develop
delay disappoint earlier stage pipelin asset earlier signific eros
compani legaci product biosimilar innov competit shortfal
compani effort improv oper margin would also materi affect outlook
valuat would larg dilut acquisit therapeut area platform
believ teva remain pressur due overhang long approv
fremanezumab delay continu headwind copaxon
sandoz nv gener potenti other sale declin
us gener outer year believ consensu underestim rate teva
under-perform price target
ebitda ev/ebitda multipl drive teva lower
higher-than-expect number new gx launch lower-than-expect number competitor
copaxon key brand product austedo fremanezumab perform expect
ip royalti teva
licens clazakizumab
net incom loss equiti
dividend pref convert
net incom loss common
sec file leerink partner research
alder bs cf mm
chang
sec file leerink partner research
termin valu discount
sec file leerink partner research
million
corp partner revenue incl royalti
po probabl success fda approv
leerink partner research compani file
million
sale
total expens exclud revenue sharing/incl sg
 total revenu
sg total revenu excl profit share
profit share total revenu
leerink partner research compani file
analysi stock price leerink target
method model larg cap healthcar growth stock ep multipl
ep appli amgen ep
leerink updat ep estim
current averag ep multipl consensu ep
compar slow grow us eu larg cap biopharma
impli target price ep
revenu multipl appli leerink revenu forecast
leerink updat revenu estim
current averag larg cap biopharma multipl revenu
impli valu fy revenu
impli target price ep use us pharma compar
method dcf adjust debt declin flow
stabl termin cash flow growth discount
present valu flow termin valu
averag method
leerink partner research compani file factset
number except per share data
share assoc co
net debt ebitda ratio
number except per share data
number except per share data
number except per share data
disclos ftf notabl pipelin
viagra sildenafil dec settlement exclus
viread tenofovir dec settlemnet exclus
reyataz atazanavir dec settlement exclus
byetta exenatid inj oct settlement exclus
effient prasugrel launch patent expiri oct
butran launch sept patent expir
nuvar appeal state patent valid pend approv
renvela assum approv pend approv
acanya jul settlement exclus approv
pazeo settlement may pend approv
exjad assum month patent expiri approv
moviprep settlement sept pend approv
solodyn feb feb launch specif strength approv
uceri assum patent invalid hold oct launch pend approv
letairi undisclos settlement assum month last patent pend approv
levitra assum month patent tent approv
restasi patent invalid await appeal assum launch pend approv
number except per share data
noxafil drt assum compound patent expir jul hold pend approv
zubsolv sept patent upheld court pend approv
latuda lost jan patent tent approv
rozerem undisclos settlement assum jul compound expiri approv
zyclara settlement jul pend approv
vigamox assum month patent expiri approv
abraxan ode exclus pend approv
absorica settlement dec pend approv
silenor settlement jan exclus approv
tarceva undisclos settlement assum may expiri polymorph patent pend approv
diclegi assum month patent expiri approv
atripla/truvada undisclos settlemnet assum last patent emtricitabin expir gate approv
rayo settlement approv
xopenex hfa assum month patent expiri pend approv
onglyza franchis patent upheld court pend approv
disclos ftf notabl pipelin sub-tot
number except per share data
number except per share data
number except per share data
number except per share data
number except per share data
number except per share data
asset held sale
sale reserv allow
liabil held sale
tax long-term liabil
senior note loan
number except per share data
adjust reconcil ni net cash oper
impair long-liv asset
net gain loss sale long-liv assets/invest
translat adjust due venezuela devalu
research develop process
impair equiti invest net
decreas increas work capit
sale purchas busi net cash acquir
proce sale long-liv asset invest
purchas properti plant equip capital-expenditure
purchas invest asset
net invest
dividend paid ordinari share
proce issuance/ purchas ordinari share net
proce issuanc prefer share net
dividend paid prefer share
dividend paid non-control interest
proce exercis option employe
purchas treasuri shares/ ordinari share
net financ
translat adjust cash cash equival
net chang equival
